The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar 5 – Focus on genetic screening by hospital pharmacists
Affiliation
Leiden University Medical Center
Country
The Netherlands
1. Current Status, Position
Professor of Clinical Pharmacy/Chair Dept. Clinical Pharmacy & Toxicology at the Leiden Univesrity Medical Center.
2. Education
Dr. Guchelaar studied pharmacy at the School of Pharmacy, State University Groningen, The Netherlands, and finished his doctoral exam Pharmacy (cum laude) in 1988 and his Pharm D exam in 1989. He was trained in hospital pharmacy at the department of Pharmacy, University Medical Centre Groningen, The Netherlands, and was a licensed Hospital Pharmacist Specialist in 1992. Then, he completed a Ph D in Medicine in 1993 and was a licensed clinical pharmacologist by the Dutch Society of Clinical Pharmacology and Biopharmacy. From 1992-1996 he worked as a hospital pharmacist – head drug manufacturing department at the department of pharmacy, Hospital Medisch Spectrum Twente in Enschede; from 1996-1998 as hospital pharmacist – head clinical pharmaceutical and toxicological laboratory at the department of pharmacy, University Medical Centre (AMC) in Amsterdam; from 1998-2003 as Chair department of Pharmacy, University Medical Centre (AMC) in Amsterdam. Since 2003 he has been appointed Chair of the department Clinical Pharmacy & Toxicology, Leiden University Medical Centre (LUMC) in Leiden and Professor of Clinical Pharmacy, School of Medicine, University of Leiden, The Netherlands. Since October 2009, he is also appointed professor of Clinical Pharmacy at the Leiden-Amsterdam Center of Drug Resaerch, Faculty of Science, University of Leiden and Director of The Leiden Center for Translational Drug Discovery and Development (LCTD3).
3. Research Area
His main key area interest is pharmacogenetics.